Researchers at the Chinese Academy of Sciences have engineered a method to mass-produce natural killer (NK) cells from cord blood stem cells, potentially making cancer immunotherapy far cheaper and more accessible. Led by Prof. Wang Jinyong, the team took a single CD34+ stem cell from donated umbilical cord blood and expanded it through a three-stage process, generating up to 14 million tumor-killing NK cells — including 7.6 million CAR-equipped versions designed to target specific cancers.
The technique uses roughly 1/140,000 to 1/600,000 of the viral vector typically required for mature NK cell modification, dramatically cutting production costs. One-fifth of a typical cord blood unit could theoretically yield thousands to tens of thousands of treatment doses. In laboratory tests on leukemia models, the cells demonstrated powerful tumor-killing ability, and critically, zero T cells were found mixed in — removing a common safety concern.
The findings, published in Nature Biomedical Engineering on February 17, were funded by China's Ministry of Science and Technology and the National Natural Science Foundation of China. If validated in clinical trials, the approach could transform NK cell therapy from an expensive, small-batch treatment into a scalable off-the-shelf cancer weapon.
